(ANSA) - BRUSSELS, SEPTEMBER 06 - "People with severely weakened immune systems who do not achieve an adequate level of protection from their standard primary vaccination may need an 'additional' dose as part of their primary vaccination". This is what the European Medicines Agency (Ema) reports while the evaluation of the data on the use of a third additional dose of an mRNA vaccine (Comirnaty by Pfizer-BioNTech or SpikeVax by Moderna) is underway in people who are severely immunocompromised, i.e. with a weakened immune system. .
The EMA will communicate the outcome of the assessments "in due course".
(HANDLE).